Are you Dr. Huang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 58 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
875 Blake Wilbur Dr
Thoracic Oncology Cancer Center
Palo Alto, CA 94304Phone+1 650-498-6000
Summary
- Dr. Jane Huang, MD is a hematologist in Palo Alto, California. She is currently licensed to practice medicine in California. She is affiliated with Stanford Health Care and VA Palo Alto Heath Care.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2002 - 2004- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1998 - 2001
University of Washington School of MedicineClass of 1998
Certifications & Licensure
CA State Medical License 1999 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 22 citationsZanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial.Peter Hillmen, Barbara Eichhorst, Jennifer R Brown, Nicole Lamanna, Susan M O'Brien
Journal of Clinical Oncology. 2023-02-10 - 4 citationsUse of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.Michael F Gensheimer, Divya Gupta, Manali I Patel, Touran Fardeen, Rachel Hildebrand
JCO Oncology Practice. 2023-02-01 - 36 citationsZanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single...Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke
The Lancet. Haematology. 2023-01-01
Press Mentions
BeiGene Presents Updated Safety and Efficacy Findings on BRUKINSA (Zanubrutinib) in BTK Inhibitor-Intolerant Patients with Relapsed or Refractory B-cell MalignanciesDecember 11th, 2021- ASH: Chasing AbbVie and J&J's Imbruvica, BeiGene's Brukinsa Fleshes Out Competitive Leukemia Data AgainNovember 4th, 2021
- BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual MeetingNovember 4th, 2021
- Join now to see all
